Shenzhen Neptunus Bioengineering Co Ltd Asset Resilience Ratio
Shenzhen Neptunus Bioengineering Co Ltd asset resilience ratio. Shenzhen Neptunus Bioengineering Co Ltd (000078) has an Asset Resilience Ratio of 0.42% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Shenzhen Neptunus Bioengineering Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shenzhen Neptunus Bioengineering Co Ltd (2001–2025)
Asset resilience ratio of Shenzhen Neptunus Bioengineering Co Ltd from 2001 to 2025. This chart shows how Shenzhen Neptunus Bioengineering Co Ltd's Asset Resilience Ratio has changed over time. Read 000078 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Neptunus Bioengineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Shenzhen Neptunus Bioengineering Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥107.89 Million | 0.42% |
| Total Liquid Assets | CN¥107.89 Million | 0.42% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen Neptunus Bioengineering Co Ltd maintains only 0.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Neptunus Bioengineering Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shenzhen Neptunus Bioengineering Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Shenzhen Neptunus Bioengineering Co Ltd Asset Resilience Ratio by Year (2001–2025)
Shenzhen Neptunus Bioengineering Co Ltd asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Shenzhen Neptunus Bioengineering Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.44% | CN¥116.80 Million ≈ $17.09 Million |
CN¥26.33 Billion ≈ $3.85 Billion |
+0.01pp |
| 2024-12-31 | 0.44% | CN¥125.43 Million ≈ $18.35 Million |
CN¥28.80 Billion ≈ $4.21 Billion |
-0.17pp |
| 2023-12-31 | 0.60% | CN¥194.41 Million ≈ $28.45 Million |
CN¥32.30 Billion ≈ $4.73 Billion |
+0.00pp |
| 2022-12-31 | 0.60% | CN¥217.71 Million ≈ $31.86 Million |
CN¥36.25 Billion ≈ $5.30 Billion |
+0.51pp |
| 2021-12-31 | 0.09% | CN¥35.21 Million ≈ $5.15 Million |
CN¥37.60 Billion ≈ $5.50 Billion |
-0.51pp |
| 2020-12-31 | 0.60% | CN¥239.48 Million ≈ $35.04 Million |
CN¥39.72 Billion ≈ $5.81 Billion |
+0.57pp |
| 2019-12-31 | 0.03% | CN¥13.16 Million ≈ $1.93 Million |
CN¥41.17 Billion ≈ $6.02 Billion |
+0.99pp |
| 2018-12-31 | -0.96% | CN¥-393.95 Million ≈ $-57.65 Million |
CN¥41.13 Billion ≈ $6.02 Billion |
+0.23pp |
| 2017-12-31 | -1.19% | CN¥-367.86 Million ≈ $-53.83 Million |
CN¥30.86 Billion ≈ $4.52 Billion |
+0.35pp |
| 2016-12-31 | -1.54% | CN¥-256.95 Million ≈ $-37.60 Million |
CN¥16.66 Billion ≈ $2.44 Billion |
+0.49pp |
| 2015-12-31 | -2.03% | CN¥-259.32 Million ≈ $-37.95 Million |
CN¥12.76 Billion ≈ $1.87 Billion |
+1.64pp |
| 2014-12-31 | -3.68% | CN¥-353.99 Million ≈ $-51.80 Million |
CN¥9.63 Billion ≈ $1.41 Billion |
-0.52pp |
| 2013-12-31 | -3.15% | CN¥-252.81 Million ≈ $-36.99 Million |
CN¥8.02 Billion ≈ $1.17 Billion |
-3.15pp |
| 2012-12-31 | 0.00% | CN¥140.92K ≈ $20.62K |
CN¥5.86 Billion ≈ $858.02 Million |
0.00pp |
| 2011-12-31 | 0.00% | CN¥132.87K ≈ $19.44K |
CN¥4.84 Billion ≈ $707.56 Million |
0.00pp |
| 2010-12-31 | 0.00% | CN¥134.46K ≈ $19.68K |
CN¥4.15 Billion ≈ $606.95 Million |
0.00pp |
| 2009-12-31 | 0.00% | CN¥125.41K ≈ $18.35K |
CN¥3.16 Billion ≈ $463.10 Million |
0.00pp |
| 2008-12-31 | 0.00% | CN¥122.23K ≈ $17.89K |
CN¥2.78 Billion ≈ $406.44 Million |
+0.00pp |
| 2007-12-31 | 0.00% | CN¥121.73K ≈ $17.81K |
CN¥3.12 Billion ≈ $456.79 Million |
+0.00pp |
| 2006-12-31 | 0.00% | CN¥100.00K ≈ $14.63K |
CN¥3.52 Billion ≈ $515.44 Million |
-3.71pp |
| 2005-12-31 | 3.72% | CN¥148.16 Million ≈ $21.68 Million |
CN¥3.99 Billion ≈ $583.30 Million |
-4.21pp |
| 2004-12-31 | 7.92% | CN¥295.35 Million ≈ $43.22 Million |
CN¥3.73 Billion ≈ $545.50 Million |
+7.43pp |
| 2003-12-31 | 0.49% | CN¥19.72 Million ≈ $2.89 Million |
CN¥4.03 Billion ≈ $589.64 Million |
-0.18pp |
| 2002-12-31 | 0.67% | CN¥23.00 Million ≈ $3.37 Million |
CN¥3.43 Billion ≈ $501.82 Million |
-0.44pp |
| 2001-12-31 | 1.11% | CN¥33.87 Million ≈ $4.96 Million |
CN¥3.04 Billion ≈ $445.38 Million |
-- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company also provides distribution of medical devices, and other medical supplies, as well as related value-added services. It serves medical institutions, drug retailers, and distributors. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 19… Read more